TRPV4 antagonists: a patent review (2015–2020)

References

• Venkatachalam K, Montell C. TRP channels. Annu Rev Biochem. 2007;76(1):387–417.
   PubMedGoogle Scholar
• Samanta A, Hughes TET, Moiseenkova-Bell VY. Transient receptor potential (TRP) channels. Subcell Biochem. 2018;87:141–165.
   PubMedGoogle Scholar
• Moran MM. TRP channels as potential drug targets. Annu Rev Pharmacol Toxicol. 2018;58(1):309–330.
   PubMedGoogle Scholar
• Wissenbach U, Bodding M, Freichel M, et al. Trp12, A novel Trp related protein from kidney. FEBS Lett. 2000;485(2–3):127–134.
   PubMed Web of Science ®Google Scholar
• Liedtke W, Choe Y, Martí-Renom MA, et al. Vanilloid receptor-related osmotically activated channel (VR-OAC), a candidate vertebrate osmoreceptor. Cell. 2000;103(3):525–535.
   PubMed Web of Science ®Google Scholar
• Strotmann R, Harteneck C, Nunnenmacher K, et al. OTRPC4, a nonselective cation channel that confers sensitivity to extracellular osmolarity. Nat Cell Biol. 2000;2(10):695–702.
   PubMed Web of Science ®Google Scholar
• Hellwig N, Albrecht N, Harteneck C, et al. Homo- and heteromeric assembly of TRPV channel subunits. Cell Sci. 2005;118(5):917–928.
   PubMed Web of Science ®Google Scholar
• Ma X, Cheng KT, Wong CO, et al. Heteromeric TRPV4–C1 channels contribute to store-operated Ca2+ entry in vascular endothelial cells. Cell Calcium. 2011;50(6):502–509.
   PubMed Web of Science ®Google Scholar
• Stewart AP, Smith GD, Sanford RN, et al. Atomic force microscopy reveals the alternating subunit arrangement of the TRPP2-TRPV4 heterotetramer. Biophys J. 2010;99(3):790–797.
   PubMed Web of Science ®Google Scholar
• White JP, Cibelli M, Urban L, et al., TRPV4: molecular conductor of a diverse orchestra. Physiol Rev. 2016;96(3):911–973.
   PubMed Web of Science ®Google Scholar
• Trpchannel.org [Internet]. Korea (KR): TRIP database. 2010 [cited 2020 Oct 9]. Available from: http://trpchannel.org/summaries/TRPV4
   Google Scholar
• Cao DS, Yu SQ, Premkumar LS. Modulation of transient receptor potential vanilloid 4-mediated membrane currents and synaptic transmission by protein kinase C. Mol Pain. 2009;5:1–20.
   PubMed Web of Science ®Google Scholar
• Fan HC, Zhang X, McNaughton PA. Activation of the TRPV4 ion channel is enhanced by phosphorylation. J Biol Chem. 2009;284(41):27884–27891.
   PubMed Web of Science ®Google Scholar
• Peng H, Lewandrowski U, Müller B, et al. Identification of a protein kinase C-dependent phosphorylation site involved in sensitization of TRPV4 channel. Biochem Biophys Res Commun. 2010;391(4):1721–1725
   PubMed Web of Science ®Google Scholar
• Voets T, Prenen J, Vriens J, et al. Molecular determinants of permeation through the cation channel TRPV4. J Biol Chem. 2002;277(37):33704–33710.
   PubMed Web of Science ®Google Scholar
• Deng Z, Paknejad N, Maksaev G, et al., Cryo-EM and X-ray structures of TRPV4 reveal insight into ion permeation and gating mechanisms. Nat Struct Mol Biol. 2018;25(3):252–260.
   PubMed Web of Science ®Google Scholar
• Hilton JK, Kim M, Van Horn WD. Structural and evolutionary insights point to allosteric regulation of TRP ion channels. Acc Chem Res. 2019;52(6):1643–1652.
   PubMed Web of Science ®Google Scholar
• Darby WG, Grace MS, Baratchi S, et al. Modulation of TRPV4 by diverse mechanisms. Int J Biochem Cell Biol. 2016;78:217–228.
   PubMed Web of Science ®Google Scholar
• Nilius B, Voets T. The puzzle of TRPV4 channelopathies. EMBO Rep. 2013;14(2):152–163.
   PubMed Web of Science ®Google Scholar
• Atobe M, Nagami T, Muramatsu S, et al. Discovery of novel transient receptor potential vanilloid 4 (TRPV4) agonists as regulators of chondrogenic differentiation: identification of quinazolin-4(3H)-ones and in vivo studies on a surgically induced rat model of osteoarthritis. J Med Chem. 2019;62(3):1468–1483.
   PubMed Web of Science ®Google Scholar
• Atobe M. Activation of Transient receptor potential vanilloid (TRPV) 4 as a therapeutic strategy in osteoarthritis. Curr Top Med Chem. 2019;19(24):2254–2267.
   PubMed Web of Science ®Google Scholar
• Gradilone SA, Masyuk TV, Huang BQ, et al. Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD gastroenterology. Gastroenterology. 2010;139(1):304–314.
   PubMed Web of Science ®Google Scholar
• Xu S, Liu B, Yin M, et al. A novel TRPV4-specific agonist inhibits monocyte adhesion and atherosclerosis. Oncotarget. 2016;7(25):37622–37635.
   PubMedGoogle Scholar
• Thoppil RJ, Adapala RK, Cappelli HC, et al. TRPV4 channel activation selectively inhibits tumor endothelial cell proliferation. Sci Rep. 2015;5(1):14257.
   PubMedGoogle Scholar
• Peters AA, Jamaludin SYN, Yapa KTDS, et al. Oncosis and apoptosis induction by activation of an overexpressed ion channel in breast cancer cells. Oncogene. 2017;36(46):6490–6500.
   PubMed Web of Science ®Google Scholar
• Grace MS, Bonvini SJ, Belvisi MG, et al. Modulation of the TRPV4 ion channel as a therapeutic target for disease. Pharmacol Ther. 2017;177:9–22.
   PubMed Web of Science ®Google Scholar
• Goldenberg NM, Ravindran K, Kuebler WM. TRPV4: physiological role and therapeutic potential in respiratory diseases. Naunyn Schmiedebergs Arch Pharmacol. 2015;388(4):421–436.
   PubMed Web of Science ®Google Scholar
• Xie Z, Hu H. TRP channels as drug targets to relieve itch. Pharmaceuticals. 2018;11(4):100.
   Web of Science ®Google Scholar
• Vincent F, Duncton MA. TRPV4 agonists and antagonists. Curr Top Med Chem. 2011;11(17):2216–2226.
   PubMed Web of Science ®Google Scholar
• Duncton MA. Small molecule agonists and antagonists of TRPV4. In: Szallasi, A., editor. TRP channels as therapeutic targets. San Diego (CA): Academic Press; 2015. p. 205–219.
   Google Scholar
• Lawhorn BG, Brnardic EJ, Behm DJ. Recent advances in TRPV4 agonists and antagonists. Bioorg Med Chem Lett. 2020;30(8):127022.
   PubMed Web of Science ®Google Scholar
• Goyal N, Skrdla P, Schroyer R, et al., Clinical pharmacokinetics, safety, and tolerability of a novel, first-in-class TRPV4 ion channel inhibitor, GSK2798745, in healthy and heart failure subjects. Am J Cardiovasc Drugs. 2019;19(3):335–342.
   PubMed Web of Science ®Google Scholar
• Stewart GM, Johnson BD, Sprecher DL, et al., Targeting pulmonary capillary permeability to reduce lung congestion in heart failure: a randomized, controlled pilot trial. Eur J Heart Fail. 2020;22(9):1641–1645.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline LLC. Trpv4 antagonists patent. WO2012174342. 2012.
   Google Scholar
• GlaxoSmithKline LLC. Trpv4 antagonists patent. WO2012174340. 2012.
   Google Scholar
• GlaxoSmithKline LLC. Trpv4 antagonists patent. WO2013012500. 2013.
   Google Scholar
• GlaxoSmithKline Intellectual Property (No.2) Limited. Trpv4 antagonists as antitussive agents patent. WO2018185701. 2018.
   Google Scholar
• A study to assess the effectiveness and side effects of GSK2798745 in participants with chronic cough – clinicaltrials.gov 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT03372603 [Cited 2020 Oct 9]
   Google Scholar
• Brooks CA, Barton LS, Behm DJ, et al., Discovery of GSK2798745: a clinical candidate for inhibition of transient receptor potential vanilloid 4 (TRPV4). ACS Med Chem Lett. 2019;10(8):1228–1233.
   PubMed Web of Science ®Google Scholar
• A phase I study to assess the pharmacokinetics of GSK2798745 tablets – clinicaltrials.gov 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT02925546 [Cited 2020 Oct 9]
   Google Scholar
• A first time in human study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK2798745 in healthy subjects and stable heart failure patients – clinicaltrials.gov 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT02119260 [Cited 2020 Oct 9]
   Google Scholar
• A study to evaluate the effect of the transient receptor potential vanilloid 4 (TRPV4) channel blocker, GSK2798745, on pulmonary gas transfer and respiration in patients with congestive heart failure – clinicaltrials.gov 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT02497937 [Cited 2020 Oct 9]
   Google Scholar
• Mole S, Fowler HA, Hotee S, et al. Investigating the effect of TRPV4 inhibition on pulmonary-vascular barrier permeability following segmental endotoxin challenge. Pulm Pharmacol Ther. 2020;64:101977.
   PubMed Web of Science ®Google Scholar
• Effects of GSK2798745 on alveolar barrier disruption in a segmental lipopolysaccharide (LPS) challenge model – clinicaltrials.gov 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT03511105 [Cited 2020 Oct 9]
   Google Scholar
• A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2798745 in subjects with diabetic macular edema (DME) – clinicaltrials.gov 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04292912 [Cited 2020 Oct 9]
   Google Scholar
• US Department of Health and Human Services [Internet]. United States (US): HHS leverages potential respiratory drug as chemical weapon antidote. 2017 [cited 2020 Oct 9]. Available from: https://www.phe.gov/Preparedness/news/Pages/gsk-chem.aspx
   Google Scholar
• Achanta S, Jordt SE. Transient receptor potential channels in pulmonary chemical injuries and as countermeasure targets. Ann NY Acad Sci. 2020;1480(1):73–103.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline Intellectual Property (No.2) Limited. Trpv4 antagonist patent. WO2017199199. 2017.
   Google Scholar
• Thorneloe KS, Cheung M, Bao W, et al. An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure. Sci Transl Med. 2012;4(159):159ra148.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline Intellectual Property (No.2) Limited. Trpv4 antagonists patent. WO2018055527. 2018.
   Google Scholar
• GlaxoSmithKline Intellectual Property (No.2) Limited. Trpv4 antagonists patent. WO2018055526. 2018.
   Google Scholar
• GlaxoSmithKline Intellectual Property (No.2) Limited. Trpv4 antagonists patent. WO2018055524. 2018.
   Google Scholar
• Pero JE, Matthews JM, Behm DJ, et al. Design and optimization of sulfone pyrrolidine sulfonamide antagonists of transient receptor potential vanilloid-4 with in vivo activity in a pulmonary edema model. J Med Chem. 2018;61(24):11209–11220.
   PubMed Web of Science ®Google Scholar
• Brnardic EJ, Ye G, Brooks C, et al. Discovery of pyrrolidine sulfonamides as selective and orally bioavailable antagonists of transient receptor potential vanilloid-4 (TRPV4). J Med Chem. 2018;61(21):9738–9755.
   PubMed Web of Science ®Google Scholar
• Skerratt SE, Mills JE, Mistry J. Identification of false positives in “HTS hits to lead”: the application of Bayesian models in HTS triage to rapidly deliver a series of selective TRPV4 antagonists. MedChemComm. 2013;4(1):244–251.
   Web of Science ®Google Scholar
• The Royal Society of Chemistry Conference – Ion Channels as Therapeutic Targets [Internet]. Cambridge (UK): the discovery and optimisation of a highly selective series of TRPV4 antagonists. 2013 [cited 2020 Oct 9]. Available from: https://www.rsc.org/images/Sarah_Skerratt_tcm18-237014.pdf
   Google Scholar
• Brooks CA, Barton LS, Behm DJ, et al. Discovery of GSK3527497: a candidate for the inhibition of transient receptor potential vanilloid-4 (TRPV4). J Med Chem. 2019;62(20):9270–9280.
   PubMed Web of Science ®Google Scholar
• Patterson JR, Terrell LR, Donatelli CA, et al. Design and optimization of an acyclic amine series of TRPV4 antagonists by electronic modulation of hydrogen bond interactions. J Med Chem. 2020;63(23):14867–14884.
   PubMed Web of Science ®Google Scholar
• Shionogi and Co Ltd. Aromatic 5-membered heterocyclic derivative having Trpv4-inhibiting activity patent. US2017066759. 2017.
   Google Scholar
• Shionogi and Co Ltd. Aromatic heterocyclamine derivative having Trpv4 inhibiting activity patent. US2016200721. 2016.
   Google Scholar
• Shionogi and Co Ltd. Aromatic heterocyclic five-membered ring derivative having Trpv4 inhibitory activity patent. WO2013146754. 2013.
   Google Scholar
• Shionogi and Co Ltd. Aromatic heterocyclamine derivative having Trpv4 inhibiting activity patent. WO2015046193. 2015.
   Google Scholar
• Shionogi and Co Ltd. Six-membered ring derivative having Trpv4 inhibitory activity patent. WO2015199206. 2015.
   Google Scholar
• Tsuno N, Yukimasa A, Yoshida O, et al. Discovery of novel 2ʹ,4ʹ-dimethyl-[4,5ʹ-bithiazol]-2-yl amino derivatives as orally bioavailable TRPV4 antagonists for the treatment of pain: part 1. Bioorg Med Chem Lett. 2016;26(20):4930–4935.
   PubMedGoogle Scholar
• Tsuno N, Yukimasa A, Yoshida O, et al. Discovery of novel 2ʹ,4ʹ-dimethyl-[4,5ʹ-bithiazol]-2-yl amino derivatives as orally bioavailable TRPV4 antagonists for the treatment of pain: part 2. Bioorg Med Chem Lett. 2016;26(20):4936–4941.
   PubMedGoogle Scholar
• Tsuno N, Yukimasa A, Yoshida O, et al., Pharmacological evaluation of novel (6-aminopyridin-3-yl)(4-(pyridin-2-yl)piperazin-1-yl) methanone derivatives as TRPV4 antagonists for the treatment of pain. Bioorg Med Chem. 2017;25(7):2177–2190.
   PubMed Web of Science ®Google Scholar
• The University of Utah Research Foundation. Compounds with TRPV4 activity compositions and associated methods thereof patent. US20150133411. 2015.
   Google Scholar
• The University of Utah Research Foundation. Compounds with TRPV4 activity compositions and associated methods thereof patent. WO2013169396. 2013.
   Google Scholar
• Everaerts W, Zhen X, Ghosh D, et al. Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis. Proc Natl Acad Sci U S A. 2010;107(44):19084–19089.
   PubMed Web of Science ®Google Scholar
• Donate-Macian P, Duarte Y, Rubio-Moscardo F, et al. Structural determinants of TRPV4 inhibition and identification of new antagonists with antiviral activity. Br J Pharmacol. 2020. DOI:10.1111/bph.15267.
   PubMed Web of Science ®Google Scholar
• Shionogi and Co Ltd. Aromatic heterocyclic derivative having Trpv4-inhibiting activity patent. WO2012144661. 2012.
   Google Scholar
• Kao Corporation. Rosmarinic acid derivative or salt thereof patent. WO2019244937. 2019.
   Google Scholar
• Kao Corporation. Rosmarinic acid derivative or salt thereof patent. JP2019218308. 2019.
   Google Scholar
• Kao Corporation. Trpv4 activity inhibitor patent. JP2018177738. 2018.
   Google Scholar
• Kao Corporation. Trpv4 activity inhibitor patent. WO202075764. 2020.
   Google Scholar
• Kao Corporation. Trpv4 activity inhibitor patent. JP2020059675. 2020
   Google Scholar
• Kao Corporation. Trpv4 activity inhibitor patent. JP2018104383. 2018.
   Google Scholar
• Kao Corporation. Trpv4 activity inhibitor patent. JP2016138063. 2016.
   Google Scholar
• National Institutes of Natural Sciences. Activity inhibitor and hyperesthesia inhibitor patent. JP2018127440. 2018.
   Google Scholar
• Takayama Y, Furue H, Tominaga M. 4-isopropylcyclohexanol has potential analgesic effects through the inhibition of anoctamin 1, TRPV1 and TRPA1 channel activities. Sci Rep. 2017;7(1):43132.
   PubMedGoogle Scholar
• Northeast Ohio Medical University. Methods for treating ischemic heart disease by targeting TRPV4 patent. US20200000837. 2020.
   Google Scholar
• Federation of American Societies for Experimental Biology - TRPV4 deletion improves cardiac function, structure and remodeling following myocardial infarction - Experimental Biology Meeting Abstracts [Internet]. 2017 [cited 2020 Oct 9]. Available from: https://faseb.onlinelibrary.wiley.com/doi/abs/10.1096/fasebj.31.1_supplement.lb675
   Google Scholar
• Adapala RK, Kanugula AK, Paruchuri S, et al. TRPV4 deletion protects heart from myocardial infarction-induced adverse remodeling via modulation of cardiac fibroblast differentiation. Basic Res Cardiol. 2020;115(2):14.
   PubMed Web of Science ®Google Scholar
• Duke University. Small molecule dual-inhibitors of TRPV4 and TRPA1 for sanitizing and anesthetizing patent. WO2017177200. 2017.
   Google Scholar
• Duke University. Activation of TRPV4 ion channel by physical stimuli and critical role for TRPV4 in organ-specific inflammation and itch patent. WO2014008477. 2014.
   Google Scholar
• Duke University. TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch patent. US20160199363. 2016.
   Google Scholar
• Duke University. TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch patent. WO2016028325. 2016.
   Google Scholar
• Chen Y, Fang Q, Wang Z, et al. Transient receptor potential vanilloid 4 ion channel functions as a pruriceptor in epidermal keratinocytes to evoke histaminergic itch. J Biol Chem. 2016;291(19):10252–10262.
   PubMed Web of Science ®Google Scholar
• Moore C, Cevikbas F, Pasolli HA, et al. UVB radiation generates sunburn pain and affects skin by activating epidermal TRPV4 ion channels and triggering endothelin-1 signaling. Proc Natl Acad Sci U S A. 2013;110(34):E3225–34.
   PubMed Web of Science ®Google Scholar
• Indiana University Research and Technology Corporation. Use of TRPV4 antagonists to ameliorate hydrocephalus and related materials and methods patent. US20150290206. 2015.
   Google Scholar
• Indiana University Research and Technology Corporation. Use of TRPV4 antagonists to ameliorate hydrocephalus and related materials and methods patent. WO2014089013. 2014.
   Google Scholar
• Indiana University Research and Technology Corporation. Targeting primary cilia to treat glaucoma patent. US20150231148. 2015.
   Google Scholar
• Hochstetler AE, Smith HM, Preston DC, et al. TRPV4 antagonists ameliorate ventriculomegaly in a rat model of hydrocephalus. JCI Insight. 2020;5(18):e137646.
   PubMed Web of Science ®Google Scholar
• Third affiliated of Army Medical University Field Operation Surgery Institute. Application of GSK2193874 in preparing antiglioma drugs or health-care products patent. CN108186641. 2017.
   Google Scholar
• Yang W, Wu PF, Ma JX, et al. TRPV4 activates the Cdc42/N-wasp pathway to promote glioblastoma invasion by altering cellular protrusions. Sci Rep. 2020;10(1):14151.
   PubMed Web of Science ®Google Scholar
• Shenzhen City Longgang District Otolaryngology Hospital. The TRPV4 inhibitor use and drug screening method and use thereof patent. CN110343759. 2019.
   Google Scholar
• Liu X, Zhang P, Xie C, et al. Activation of PTEN by inhibition of TRPV4 suppresses colon cancer development. Cell Death Dis. 2019;10(6):460.
   PubMedGoogle Scholar
• Sungkwang Medical Foundation. TRPV4 composition for preventing or treating spinal cord injury comprising transient receptor potential vanilloid 4 antagonist patent. KR2019090509. 2019.
   Google Scholar
• Kumar H, Lim CS, Choi H, et al. Elevated TRPV4 levels contribute to endothelial damage and scarring in experimental spinal cord injury. J Neurosci. 2020;40(9):1943–1955.
   PubMed Web of Science ®Google Scholar
• Universidad Nacional Autonoma De Mexico. Use of the antagonistic drugs of the ion channel of the transient receptor potential vaniloid 4 (TRPV4) for the macular edema treatment patent. MX2017011166. 2017.
   Google Scholar
• Arredondo Zamarripa D, Noguez Imm R, Bautista Cortés AM, et al. Dual contribution of TRPV4 antagonism in the regulatory effect of vasoinhibins on blood-retinal barrier permeability: diabetic milieu makes a difference. Sci Rep. 2017 October 12;7(1):13094.
   PubMedGoogle Scholar
• Orduña Ríos M, Noguez Imm R, Hernández Godínez NM, et al. TRPV4 inhibition prevents increased water diffusion and blood-retina barrier breakdown in the retina of streptozotocin-induced diabetic mice. PLoS One. 2019;14(5):e0212158.
   PubMed Web of Science ®Google Scholar
• Luo J, Feng J, Yu G, et al. Transient receptor potential vanilloid 4-expressing macrophages and keratinocytes contribute differentially to allergic and nonallergic chronic itch. J Allergy Clin Immunol. 2018;141(2):608–619.e7.
   PubMed Web of Science ®Google Scholar
• Boudaka A, Al-Yazeedi M, Al-Lawati I. Role of transient receptor potential vanilloid 4 channel in skin physiology and pathology. Sultan Qaboos Univ Med J. 2020;20(2):e138–e146.
   PubMedGoogle Scholar
• Guarino BD, Paruchuri S, Thodeti CK. The role of TRPV4 channels in ocular function and pathologies. Exp Eye Res. 2020;201:108257.
   PubMed Web of Science ®Google Scholar
• Yu S, Huang S, Ding Y, et al. Transient receptor potential ion-channel subfamily V member 4: a potential target for cancer treatment. Cell Death Dis. 2019;10(7):497.
   PubMedGoogle Scholar
• Morgan P, Van Der Graaf PH, Arrowsmith J, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today. 2012;17(9–10):419–424.
   PubMed Web of Science ®Google Scholar
• Simon GM, Niphakis MJ, Cravatt BF. Determining target engagement in living systems. Nat Chem Biol. 2013;9(4):200–205.
   PubMed Web of Science ®Google Scholar
• Kuebler WM, Jordt SE, Liedtke WB. Urgent reconsideration of lung edema as a preventable outcome in COVID-19: inhibition of TRPV4 represents a promising and feasible approach. Am J Physiol Lung Cell Mol Physiol. 2020;318(6):L1239–L1243.
   PubMed Web of Science ®Google Scholar
• Rosenbaum T, Benitez-Angeles M, Sanchez-Hernandez R, et al. TRPV4: a physio and pathophysiologically significant ion channel. Int J Mol Sci. 2020;21(11):3837.
   Web of Science ®Google Scholar